Irlab Therapeutics is preparing to start a Phase 3 clinical trial of mesdopetam, its experimental oral treatment intending to ease levodopa-induced dyskinesia, the uncontrolled movements affecting people with Parkinson’s disease. After announcing results of a Phase 2 trial of mesdopetam, Irlab requested an end-of-Phase 2…
A $50 million donation to the Baptist Health Foundation is set to expand care for people with Parkinson’s and other neurological diseases across South Florida and to advance research into these disorders. The donation from Kenneth C. Griffin, founder and CEO of the Miami-based hedge fund Citadel,…
A new system that uses artificial intelligence (AI) to analyze videos of people walking may help speed the diagnosis of Parkinson’s disease. Scientists at China Medical University Hospital (CMUH) in Taiwan developed the technology, which can help physicians diagnose Parkinson’s more efficiently and get patients faster access to treatment,…
Encapsulating precursor nerve cells in a collagen hydrogel can enhance the efficacy of stem cell transplantation to the brain, a potential treatment to replace dopamine-producing nerve cells that are lost in people with Parkinson’s disease, according to a preclinical study. “Our hydrogel nurtures, supports and protects the cells after…
Mesdopetam (IRL790), an investigational therapy for levodopa-induced dyskinesia in Parkinson’s disease, was found to reduce signs of psychosis in a rat model, a study reported. Psychosis is a common nonmotor symptom in people with Parkinson’s, characterized by hallucinations and/or delusions — hallucinations being things patients see, hear, or feel that…
U.S.-based Psomagen, a contract research services provider, has announced that it will lead an analysis of data from the 80,000 participants enrolled in the Global Parkinson’s Genetics Program (GP2) — an initiative seeking a better understanding of the genetic underpinnings of Parkinson’s disease. Results from the analysis,…
A new population study has provided evidence of a potential causal link between exposure to an air pollutant called fine particular matter (PM2.5) and the development of Parkinson’s disease in the U.K. Data also showed that exposure to ground-level ozone, a gas that can damage the lungs, was not…
Note: This story was updated March 21, 2024, to correct that NeuroDerm is a subsidiary of Mitsubishi Tanabe Pharma Corp. ND0612, a liquid formation of levodopa/carbidopa given without interruption via an under-the-skin pump, continues to outperform standard oral levodopa/carbidopa at controlling motor symptoms in people with advanced…
When asked to quickly assess the number of people in a room, the average person tends to overcount them. In Parkinson’s disease patients with presence hallucinations — the strong sensation of a presence when no one is there — this overestimation is much more heightened when compared with patients…
Four months of daily Nuplazid (pimavanserin), an approved oral therapy for psychosis associated with Parkinson’s disease, was also found to significantly improve cognitive abilities, daily living activities, and health-related quality of life for patients in a Phase 4 study. “These findings suggest that treatment with [Nuplazid] can result…
Get regular updates to your inbox.
